利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

7 条记录 (耗时 0.018 秒)

    METHODS FOR DIAGNOSING CANCER BY CHARACTERIZATION OF TUMOR CELLS ASSOCIATED WITH PLEURAL OR SEROUS FLUIDS
    1.
    发明公开
    METHODS FOR DIAGNOSING CANCER BY CHARACTERIZATION OF TUMOR CELLS ASSOCIATED WITH PLEURAL OR SEROUS FLUIDS 审中-公开
    对于肿瘤细胞表征的癌症诊断方法，使用或胸膜浆液性液体的

    公开(公告)号：EP2737317A2

    公开(公告)日：2014-06-04

    申请号：EP12746193.7

    申请日：2012-07-27

    申请人： The Trustees Of The University Of Pennsylvania ,  Veridex, LLC

    发明人： RAO, Galla, Chandra ,  FOULK, Brad ,  ALBELDA, Steven, M. ,  SCHWED, Daniel ,  CONNELLY, Mark

    IPC分类号： G01N33/574 ,  G01N15/00

    CPC分类号： G01N33/574 ,  C12Q1/6841 ,  G01N1/40 ,  G01N1/4077 ,  G01N33/57488 ,  G01N2333/705

    摘要： A method for diagnosing or differentially diagnosing a cancer characterized by the presence of cancer cells in the pleural fluid of a mammalian subject, the method comprising contacting a sample of pleural fluid of the subject with colloidal magnetic particles coupled to a ligand which binds to a determinant on a cancer cell, but does not bind above a baseline threshold to other cellular and non-cellular components in pleural fluid; subjecting the pleural fluid-magnetic particle mixture to a magnetic field to produce a cell fraction enriched in ligand coupled-magnetic particle-bound cancer cells, if present in the pleural fluid; and analyzing the enriched fraction for the number of cancer cells in the pleural fluid. In certain aspects, this method involves preparing the pleural fluids for the above-noted method steps by, e.g., dilution of unprocessed pleural fluid. In certain aspect, the pleural fluid is subjected to the diagnostic method within 24 hours of withdrawal from the subject. This method has advantages to present diagnostic procedures for identifying malignant pleural effusions. The tumor cells present in pleural fluid can be characterized with cellular and molecular markers to determine prognostic and predictive factors.

    AUTOMATED ENUMERATION AND CHARACTERIZATION OF CIRCULATING MELANOMA CELLS IN BLOOD
    4.
    发明公开
    AUTOMATED ENUMERATION AND CHARACTERIZATION OF CIRCULATING MELANOMA CELLS IN BLOOD 有权
    自动计数和表征血液中循环黑素瘤细胞

    公开(公告)号：EP2225563A1

    公开(公告)日：2010-09-08

    申请号：EP08855440.7

    申请日：2008-10-20

    申请人： Veridex, LLC

    发明人： CONNELLY, Mark, Carle ,  RAO, Galla, Chandra ,  TERSTAPPEN, Leon

    IPC分类号： G01N33/574

    CPC分类号： G01N33/5743 ,  G01N33/57488 ,  G01N2333/70589 ,  G01N2333/70596

    摘要： The CellTracks® System provides a system to enumerate circulating melanoma cells in blood. The system immunomagnetically concentrates epithelial cells, fluorescently labels the cells and identifies and quantifies circulating melanoma cells. The absolute number of circulating melanoma cells detected in the peripheral blood tumor load is, in part, a factor in prediction of survival, time to progression, and response to therapy. Diagnosis and monitoring of melanoma has been limited by the inability to monitor circulating melanoma cells. The present invention provides a method to enumerate circulating melanoma cells in blood samples. Accordingly, this technology provides a means and device for monitoring disease progression in patients with melanoma.

    METHODS AND KITS FOR THE DETECTION OF CIRCULATING TUMOR CELLS IN PANCREATIC PATIENTS USING POLYSPECIFIC CAPTURE AND COCKTAIL DETECTION REAGENTS
    6.
    发明公开
    METHODS AND KITS FOR THE DETECTION OF CIRCULATING TUMOR CELLS IN PANCREATIC PATIENTS USING POLYSPECIFIC CAPTURE AND COCKTAIL DETECTION REAGENTS 有权
    方法和药盒中循环胰腺肿瘤患者的肿瘤细胞多特异性捕捉和鸡尾酒检测试剂的检测

    公开(公告)号：EP2628008A1

    公开(公告)日：2013-08-21

    申请号：EP11778732.5

    申请日：2011-10-13

    申请人： Veridex, LLC

    发明人： RAO, Galla, Chandra ,  CONNELLY, Mark, Carle

    IPC分类号： G01N33/543 ,  G01N33/574

    CPC分类号： G01N33/57492 ,  G01N33/54333

    摘要： A highly sensitive assay is disclosed which combines immunomagnetic enrichment with multiparameter flow cytometric or image cytometry to detect, enumerate and characterize carcinoma cells in the blood. The present invention incorporates the conjugation of different antibodies to the same ferrofluid. This has the effect of making the ferrofluid polyspecific with respect to the antigens that the ferrofluid will bind. The multiple antibodies present on the same ferrofluid do not appear to block or otherwise interfere with each other. Such ferrofluids have the highly desirable effect of being able to bind specifically to more than one type of cell. The assay is especially useful to enable the capture of CTCs that have low EpCAM expression, but high expression of other tumor markers; Accordingly, the assay facilitates the biological characterization and staging of carcinoma cells.